300+ investors in your industry, stage, and region Get
Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Andorra
Colombia
Sudan
Czech Republic
China
Armenia
Costa Rica
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Panama
Nicaragua
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Morocco
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
Ireland
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Argentina
Bangladesh
Qatar
Spain
Angola
Europe
Cyprus
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
TCD Capital, VC Fund

TCD Capital

VC Fund

Uccle, Belgium

TCD Capital is a VC fund in Uccle focused on Biotechnology and Health Care. TheClubDeal is an investment holding and fund manager co-investing into SME’s and real estate projects. It provides facilitation of governance between non-executive shareholders and entrepreneurs. Its governance structure, including its charter of avoidance of conflict of interests, is therefore paramount to the adequate management of the Company.At TheClubDeal, we connect Investors and Entrepreneurs around promising investment opportunities. For each of these, we will invest ourselves and co-invest with a selected number of investors. We add value by processing strong applied governance principles, when selecting and managing our investments, and by gathering the necessary skills to successfully grow the businesses and real-estate projects we co-invest in. TheClubDeal is launching their second fund, a 50M € PRIVAK/PRICAF in H1 2021 with the mandate to invest in Belgian scale-ups in three sectors: Smart Living, Tech and Life Sciences.

Total investments:
18
Last investment:
Lead investor:
33%
Fund size:
$49M
Last fund:

Last updated:

Industries TCD Capital invests in

BiotechnologyHealth CareMedical DeviceClinical TrialsInformation Technology

Stages TCD Capital invests in

Series ASeries BVenture - Series UnknownSeedSeries C

Countries TCD Capital invests in

BelgiumFrance

Round sizes

Series A $2.1M–$7.7MSeries B $13M–$19MVenture - Series Unknown $5.5M–$6.5M

Contacts

NameEmailPhoneSocials
See all 7 contacts →

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$2.1M–$7.7M
Series B
$13M–$19M
Venture - Series Unknown
$5.5M–$6.5M

Investment Focus

Industry

  • Biotechnology 4 (22%)
  • Health Care 3 (17%)
  • Medical Device 2 (11%)
  • Clinical Trials 2 (11%)
  • Information Technology 2 (11%)
See all 31 industries →

Stage

  • Series A 9 (50%)
  • Series B 2 (11%)
  • Venture - Series Unknown 2 (11%)
  • Seed 1 (6%)
  • Series C 1 (6%)
See all 6 stages →

Country

  • Belgium 10 (56%)
  • France 4 (22%)

Team

NameTitleInvestmentsLinksEmail
Jean-Louis Dubrule Executive partner and Board Member
Executive partner and Board Member Total investments: 0
Find email
Jean-Marc Legrand Founder & Managing Director
Founder & Managing Director Total investments: 0
Find email
Xavier de Villepin
Xavier de Villepin Business & Investment Manager
Business & Investment Manager Total investments: 0
Find email
Edouard de Becker Remy
Edouard de Becker Remy Investment Analyst
Investment Analyst Total investments: 0
Find email
Frederic Convent Senior Investment Manager
Senior Investment Manager Total investments: 0
Find email
See all 7 team members →

Investments

CompanyDescriptionRoundLinks
Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder. $6.5M / Venture - Series Unknown / Oct 29, 2024
CLOUDS OF CARE aids HealthTech firms from algorithm validation to medical device software, focusing on regulatory compliance. $5.5M / Venture - Series Unknown / Sep 04, 2024
Inpulse is an automated supply management platform for restaurateurs. $7.7M / Series A / Apr 19, 2023
Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. $43.3M / Series D / Oct 17, 2022
FLYX.cloud enables retail chains to maximise value from each customer in multiple industries (such as Food, Grocery and Fuel) and in an omni-channel sales model. $2.1M / Series A / Jun 01, 2022
Smartflats constructs and distributes a range of flats for its clients.The company provides its users with an online platform to make bookings for their stay. It enables them to make food orders and obtain transfer services. Furthermore, it provides wireless internet, TVs, coffee makers, irons, and hairdryers.Smartflats was founded in 2012 byTarik Hennen and Alexandre Szmaj. $4.9M / Series A / Oct 01, 2021
Because finding the right partner in the fast-growing digital environment is a hard task, we have built an online multi-criteria searching tool strongly linked to professional networks and peer-to-peer recommendations. Sortlist helps marketing managers find their partners in minutes and let them focus on building communication and marketingsuccess.Start your search now on www.sortlist.com $13M / Series B / Sep 15, 2021
Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. $24.5M / Series C / Dec 17, 2020
Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. Series C / Aug 31, 2020
Co-Living, Smart Living Seed / Apr 30, 2019
See all 18 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Andorra
Colombia
Sudan
Czech Republic
China
Armenia
Costa Rica
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Panama
Nicaragua
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Morocco
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
Ireland
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Argentina
Bangladesh
Qatar
Spain
Angola
Europe
Cyprus
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does TCD Capital invest in?

TCD Capital invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is TCD Capital's check size?

TCD Capital typically joins rounds of $2.1M–$7.7M at Series A, $13M–$19M at Series B and $5.5M–$6.5M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds TCD Capital participates in.

How do I contact TCD Capital?

Public channels for TCD Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at TCD Capital?

The team at TCD Capital includes Jean-Louis Dubrule (Executive partner and Board Member), Jean-Marc Legrand (Founder & Managing Director) and Xavier de Villepin (Business & Investment Manager), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
TCD Capital TCD Capital Find emails